Ankara, Turkey
Ankara, Turkey

Time filter

Source Type

NORTH WILKESBORO, N.C., May 16, 2017 (GLOBE NEWSWIRE) -- In recognition of Window World’s enduring support against childhood cancer and other life-threatening illnesses, St. Jude Children’s Research Hospital® has honored America’s largest exterior remodeler with its Organizational Support Award. Window World accepted the award at the St. Jude 2017 Partner Summit in Memphis, Tennessee. The Organizational Support Award marks the second recognition of Window World’s fundraising for St. Jude; the first came when Window World was named the hospital’s New Corporate Partner of the Year in 2010. The Organizational Support Award recognizes a corporate partner that supports the mission of St. Jude by generating awareness and raising funds through a variety of ways. With more than 200 locations nationwide, Window World employs a multi-faceted approach to giving at both a national and local level. Nationally, Window World has supported St. Jude through numerous endeavors including the Window World Day at St. Jude, the Give Thanks. Walk™, the St. Jude Presents John Rich & Friends Concert, the FedEx St. Jude Classic PGA TOUR event, and most recently, The Stinger project, which raised more than $1 million for St. Jude in one night. At the local level, Window World franchise owners do their part to generate support for St. Jude with events such as Paducah’s wine and chocolate festival, San Antonio’s charity golf events, and Tidewater’s participation in the St. Jude Dream Home® Giveaway. More than 30 locations fielded teams for the St. Jude Walk/Run to End Childhood Cancer in 2016, raising awareness and funds in their communities. “Window World is so deserving of this recognition, and its leadership, staff and customers have consistently demonstrated their generous and heartfelt commitment to St. Jude Children’s Research Hospital through numerous engagement opportunities,” said Richard Shadyac Jr., President and CEO of ALSAC, the fundraising and awareness organization for St. Jude Children’s Research Hospital. “We are incredibly grateful for Window World’s partnership, and its contributions to St. Jude are a testament to the company’s continuing dedication to helping save the lives of kids around the world fighting cancer and other life-threatening diseases.” Window World’s commitment to St. Jude began in 2008 with the inception of its charitable arm, Window World Cares, founded by Chairman and CEO of Window World, Tammy Whitworth, and her late husband, Todd Whitworth. Overwhelmed with compassion and admiration after their first visit to the hospital, Tammy and Todd decided that they would raise enough money to fund the hospital’s operation for one full day. The “One More Day” campaign was born in 2012, and to date, Window World Cares has donated more than $7 million to St. Jude. To learn more about Window World Cares and its relationship with St. Jude Children’s Research Hospital, or to make a donation, please visit To find out more about The Stinger Car, please visit For additional information on Window World, please visit About Window World® Window World®, headquartered in North Wilkesboro, N.C., is America’s largest replacement window and exterior remodeling company, with more than 200 locally-owned offices nationwide. Founded in 1995, the company sells and installs windows, siding, doors and other exterior products, with a total of over 13 million windows sold to date. Window World is an ENERGY STAR® partner and its window products have earned the Good Housekeeping Seal for ten consecutive years. In June 2016, Window World earned the ranking of “Highest in Customer Satisfaction with Windows and Doors, Three out of Four Times in a Row,” by J.D. Power. For more information about Window World, visit or call 1-800 NEXT WINDOW. Window World Cares® was founded in 2008 by Tammy Whitworth and her late husband, Todd. The foundation provides funding for St. Jude Children’s Research Hospital®, where it was named New Corporate Partner of the Year in 2010. Since its inception in 2008, the foundation has raised over $7 million for St. Jude. To learn more about Window World Cares or to donate, visit Window World received the highest numerical score among 16 companies in the J.D. Power 2016 Windows & Patio Doors Satisfaction Study, based on 2,628 total responses, measuring the experiences and perceptions of customers who purchased windows and/or patio doors in the previous 12 months, surveyed January- March 2016. Your experiences may vary. Visit

SEATTLE--(BUSINESS WIRE)--Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced that it will present key clinical updates in partnership with its collaborators on its investigational products JCAR017 and JCAR014 at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting 2017 in Chicago, Illinois, June 2-6. JCAR017 and JCAR014 are chimeric antigen receptor (CAR) T cell product candidates that target CD19, a protein expressed on the surface of almost all B cell malignancies, including non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL). While the manufacturing process and final cell product differ, both product candidates utilize the 4-1BB co-stimulatory domain and use a defined cell manufacturing process, controlling the type of cells a patients receives with the goal of delivering an improved therapeutic benefit. Insights from studies of the translational product JCAR014 are being applied to the development of JCAR017. New data from the ongoing Phase I TRANSCEND NHL 001 trial (NCT02631044) evaluating JCAR017 in adult patients with relapsed or refractory aggressive NHL [diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), follicular lymphoma Grade 3B, and mantle cell lymphoma (MCL)] will be presented, with increased patient numbers and longer duration of follow-up reported at two dose levels as compared to previous presentations. Updated safety data will also be presented from the ongoing Phase I trial (NCT01865617) evaluating JCAR014 in adult patients with relapsed or refractory ALL, NHL, or CLL. The JCAR014 presentation will also include data on clinical and laboratory biomarkers that may allow early identification of cytokine release syndrome (CRS) and neurotoxicity (NT). Juno’s CAR and TCR technologies genetically engineer T cells to recognize and kill cancer cells. Juno’s CAR T cell technology inserts a gene for a particular CAR into the T cell, enabling it to recognize cancer cells based on the expression of a specific protein located on the cell surface. Juno’s TCR technology provides the T cells with a specific T cell receptor to recognize protein fragments derived from either the surface or inside the cell. When either type of engineered T cell engages the target protein on the cancer cell, it initiates a cell-killing response against the cancer cell. JCAR014 and JCAR017 are investigational product candidates and their safety and efficacy have not been established. They are not approved by any regulatory authority. Juno Therapeutics is building a fully integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B cell malignancies as well as multiple solid tumors. Several product candidates have shown compelling clinical responses in clinical trials in refractory leukemia and lymphoma conducted to date. Juno's long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases. Juno brings together innovative technologies from some of the world's leading research institutions, including the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children's Research Institute (SCRI), the University of California, San Francisco, and The National Cancer Institute. Juno Therapeutics has an exclusive license to the St. Jude Children’s Research Hospital patented technology for CD19-directed product candidates that use 4-1BB, which was developed by Dario Campana, Chihaya Imai, and St. Jude Children’s Research Hospital. Juno’s product candidate JCAR017 was developed in collaboration with SCRI and others. Celgene Corporation and Juno Therapeutics formed a collaboration in June 2015, under which the two companies will leverage T cell therapeutic strategies to develop treatments for patients with cancer and autoimmune diseases with an initial focus on chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies. In April 2016, Celgene exercised its option to develop and commercialize the Juno CD19 program outside North America and China. This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including statements regarding Juno’s mission, progress, clinical benefits, clinical trial results and the implications thereof, planned presentations at ASCO, clinical trial plans, emerging medical trends, and the potential of biomarkers to allow early identification of serious toxicities. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from such forward-looking statements, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to, risks associated with: the success, cost, and timing of Juno's product development activities and clinical trials; Juno's ability to obtain regulatory approval for and to commercialize its product candidates; Juno's ability to establish a commercially-viable manufacturing process and manufacturing infrastructure; regulatory requirements and regulatory developments; success of Juno's competitors with respect to competing treatments and technologies; Juno's dependence on third-party collaborators and other contractors in Juno's research and development activities, including for the conduct of clinical trials and the manufacture of Juno's product candidates; Juno's dependence on Celgene for the development and commercialization outside of North America and China of Juno’s CD19 product candidates and any other product candidates for which Celgene exercises an option; Juno’s dependence on JW Biotechnology (Shanghai) Co., Ltd, over which Juno does not exercise complete control, for the development and commercialization of product candidates in China; Juno's ability to obtain, maintain, or protect intellectual property rights related to its product candidates; amongst others. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Juno's business in general, see Juno's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 4, 2017 and Juno’s other periodic reports filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Juno disclaims any obligation to update these forward-looking statements.

News Article | May 18, 2017

For nearly three decades, prominent actor and equine lover William Shatner has taken on perhaps his most significant role, not on TV or in film, but in real life as a tireless advocate for underrepresented communities, raising tens of millions of dollars to support hundreds of worthy charitable organizations by way of his annual philanthropic horse show event. Now in its 27th year, Shatner’s annual event, the Hollywood Charity Horse Show Sponsored by Wells Fargo, will return once again on Saturday, June 3, at the Los Angeles Equestrian Center, Southern California’s premier equestrian facility, with this year’s special musical guest Roadcase Royale, started by Nancy Wilson of Heart and Liv Warfield of Prince’s New Power Generation. The Hollywood Charity Horse Show will kick off with an hour-long free Arena Show, which is completely open to the public, beginning at 5:30 p.m. and bringing together an array of world-class reining horses and their riders competing for top honors in the expansive 3,500-seat Equidome (480 Riverside Drive, Burbank). During the not-to-be-missed Arena Show, spectators will be treated to rare and exquisite performances by the Sicilian Tenors and award-winning singer and military veteran Judy Welch of CRE Outreach, as well as a special riding demonstration by AHEAD with Horses, a longtime beneficiary of the event. The dinner will begin shortly thereafter at 7 p.m. in the lovely Equestrian Ballroom, coinciding with an online silent auction featuring hundreds of extraordinary unique and signed items, including props from TV’s “Outlander,” “Once Upon a Time,” “Vampire Diaries,” “The Originals,” and “Doctor Who,” and films, such as X-Men, Captain America, Thor, and Star Trek. Those wanting to participate in the auction can go to The auction will close Sunday, June 4 at 12 noon PT. The Rock and Roll Hall-of-Famer Wilson, along with Warfield, both fronting the new sextet band Roadcase Royale, will then bring their passionate and rich mix of rock and R&B to life for dinner guests during the 45-minute live set. The band’s new politically charged hard rock anthem, "Not Giving Up," is available now through most digital retail outlets, including iTunes and Amazon, and also on streaming services, such as Apple Music and Spotify. Past years’ dinners have featured other legendary musical acts including Sheryl Crow, Vince Gill, Joe Walsh, Randy Travis, Brad Paisley, Neal McCoy, Ben Folds, Willie Nelson and Wynonna Judd. Proceeds from this year’s event will benefit more than two dozen charitable organizations, including A Place Called Home, AHEAD With Horses, ALSAC / St. Jude Children’s Research Hospital, American Legion Legacy Scholarship Fund, Blind Children’s Center, BraveHearts Therapeutic Riding & Educational Center, Caterina’s Club, Children’s Hospital Los Angeles, The Colburn School, CRE Outreach, Dream Catcher of L.A., E.L.S.A. (Experience Learning Support with Animals), Friendly House LA, Friends & Helpers, Gay Men’s Chorus of Los Angeles, Hollenbeck Police Activities League, Horses4Heroes, Inner-City Youth Orchestra of Los Angeles, Painted Turtle Gang Camp Foundation, Pasadena Playhouse, Pets for Vets, Queen of Hearts, REINS Therapeutic Horsemanship Program, Saddles for Soldiers, Village Family Services and Wright Foundation for Pediatric Ophthalmology and Strabismus. “I am thrilled to be able to present this show one more year,” said Shatner. For more information on the 2017 William Shatner’s Hollywood Charity Horse Show Sponsored by Wells Fargo, or to purchase tickets or sign up for online auction bidding, visit About Hollywood Charity Horse Show Sponsored by Wells Fargo The Hollywood Charity Horse Show, headed by William & Elizabeth Shatner, is in its 27th year raising funds for organizations in Los Angeles, California for children’s health care and other programs. About Roadcase Royale Led by Liv Warfield of Prince’s New Power Generation and Nancy Wilson of Heart, Roadcase Royale has a rich background in rock and R&B. Warfield, Wilson, and their bandmates bring their decades of experience from the upper echelon of the music industry to Roadcase Royale, along with a renewed sense of direction and drive. Joining Wilson and Warfield are Warfield’s lead guitarist and musical director Ryan Waters and Heart veterans Dan Rothchild (bass), Ben Smith (drums) and Chris Joyner (keys). Each of these members shine in Roadcase Royale with their various sensibilities creating the group’s sensitive, passionate, and driving rock and R&B sound. For more info, visit

NEW YORK--(BUSINESS WIRE)--On Thursday, May 18, 2017, Roy Israel, NAM’s President and CEO, will be honored by the Long Island Business News when he receives the prestigious Executive Circle Award 2017. The Executive Circle Awards celebrate C-suite and senior level executives and directors who consistently demonstrate remarkable leadership skills, integrity, values, vision, a commitment to excellence, company performance, community service and diversity. Roy Israel, an innovative entrepreneur and business executive, founded NAM (National Arbitration and Mediation) in 1992. NAM, a private forum to resolve disputes outside the public court system, provides a cost-effective alternative to expensive and often time-consuming litigation. This year, the firm marks its 25th anniversary in the Alternative Dispute Resolution (ADR) business. Although ADR is a permanent and accepted part of the legal landscape today, in the industry’s nascent stages, Mr. Israel spent a great deal of time introducing the benefits of ADR to a vast number of practicing attorneys, law firms, insurance companies and corporate entities. Under Mr. Israel’s leadership, NAM has grown significantly over the past 25 years to become one of the nation’s largest alternative dispute resolution providers. More than 50% of the Fortune 100 companies and more than 10,000 commercial entities utilize NAM’s services. The company administrates thousands of cases each year in a wide array of practice areas which include, but are not limited to, Complex Commercial, Construction, Employment, Entertainment, Financial Services, International, Insurance, Medical Malpractice, Personal Injury, Professional Liability and Real Estate dispute resolution. NAM has nearly 2,500 top-tier neutrals on its roster and provides ADR services in all 50 states, Puerto Rico and major cities around the world. Under Mr. Israel’s direction, NAM was voted the #1 ADR provider in the United States for the second year in a row and its mediators were voted #1, 2 and 3 in the country by the 2017 National Law Journal Annual Reader Rankings Survey. Further, the company was ranked a Best National ADR Provider by the 2017 Corporate Counsel Best of Survey. NAM was also named the #1 ADR firm by The New York Law Journal Reader Rankings Survey for the last six years, and its neutrals comprise 9 of the Top 10 Mediators and 8 of the Top 10 Arbitrators in New York State. Additionally, Mr. Israel, along with 7 of NAM’s neutrals, was named a National Law Journal 2016 Alternative Dispute Resolution Champion, as part of a select group of only 48 nationwide. NAM also received the ADR Provider of the Year award from the American College of Civil Trial Mediators and has consistently been rated as one of Long Island’s Top 100 Companies. Mr. Israel introduced technology to the ADR field in the development of myADR and the myADR mobile app. myADR is a unique patented dispute resolution case management system designed to enable NAM’s clients to manage their ADR cases online and via their mobile devices. Today, myADR is used daily by many of the nation’s largest insurers and most prominent law firms. Roy Israel has lectured at numerous bar association meetings, insurance companies and law firms as an expert in ADR, as well as a speaker for various legal education programs. He has been a featured expert on the subject of alternative dispute resolution on ABC World News Tonight, Fox Network News, Court TV, CNBC, Channel 5 New York and Bloomberg Radio. Additionally, he has been quoted or the company has been mentioned in more than 150 various Associated Press articles nationwide, as well as Newsday, the Wall Street Journal, USA Today, New York Post, Treasury & Risk Management, Insurance Advocate, Claims Magazine and numerous other publications. NAM continuously strives to help make a difference by getting involved with more than 30 charitable organizations and events throughout the year that benefit children and their families. Some of those charities include Alley Oop for Autism, Autism Speaks, Charley’s Fund, Crohn’s & Colitis Foundation of America, Make A Wish Foundation, St. Jude Children’s Research Hospital and Toys For Tots. Mr. Israel was also the recipient of the Institute of Jewish Humanities prestigious Entrepreneur with Vision Award for his impressive achievements and significant contributions in the area of private ADR. Click below to view the 2017 National Law Journal Reader Rankings Survey Click below to view the 2016 New York Law Journal Reader Rankings Survey Click below to view The National Law Journal 2016 Alternative Dispute Resolution Champions Founded in 1992, NAM (National Arbitration and Mediation) has been recognized for its superb customer service and exceptional panel of arbitrators and mediators. In 2017, NAM was named Best ADR firm in the United States by the National Law Journal Annual Reader Rankings Survey for the second year in a row. Further, the company was ranked a Best National ADR Provider by the 2017 Corporate Counsel Best of Survey. Consistent with being the nation's premier ADR provider, the New York Law Journal Annual Reader Rankings Survey also selected NAM as the #1 ADR firm for the last six years. Additionally, 7 of NAM's neutrals were named National Law Journal 2016 Alternative Dispute Resolution Champions, as part of a select group of only 48 nationwide. NAM actively works with more than 10,000 commercial entities, including more than 50% of the Fortune 100 companies. NAM offers litigants a nationwide panel of nearly 2,500 top-tier former judges and practicing specialists uniquely qualified to facilitate the resolution of disputes in a private forum. The company maintains rosters in all 50 states, Puerto Rico and in major cities around the world, with specific expertise in the areas of Complex Commercial, Construction, Employment, Entertainment, Financial Services, International, Insurance, Medical Malpractice, Personal Injury (including 3rd party and 1st party actions), Professional Liability and Real Estate dispute resolution. NAM is often an indispensable resource for parties seeking cost-effective alternatives to expensive and often time-consuming litigation.

Under Shadyac, Jr.'s, leadership since 2009, the American Lebanese Syrian Associated Charities (ALSAC) has become the largest healthcare charity in America, generating more than 75 percent of funds needed to operate and sustain St. Jude Children's Research Hospital. Paul Ayoub, chairman of the board of ALSAC said, "It was so fitting for Rick to be honored on Ellis Island, one of America's greatest symbols of immigrant history. The grandson of Lebanese immigrants, Rick has spent his entire life devoted to St. Jude founder Danny Thomas' vision that no child die in the dawn of life. St. Jude was founded on the principle that all children regardless of race, religion or ability to pay would be treated equally. Today St. Jude has taken the overall childhood cancer survival rates from 20 percent to 80 percent, and we will not stop until no child dies from cancer. The story of the founding of ALSAC and St. Jude Children's Research Hospital is a beautiful immigrant story that should forever be celebrated." His father, Richard Shadyac, Sr., received the Ellis Island Medal of Honor in 1999 when he served as ALSAC CEO. Shadyac, Sr., was personally tapped by Danny Thomas from the beginning to help with fundraising needed to begin St. Jude Children's Research Hospital. Danny Thomas  opened St. Jude in 1962 as a way to say thank you to God and the United States of America for the opportunities given to him and his fellow citizens of Arab descent. Today, St. Jude is supported by millions of generous donors from communities everywhere. Danny's daughter, Marlo Thomas, National Outreach Director for St. Jude, also received the Ellis Island Medal of Honor in 1999 following in the footsteps of her father who received the honor in 1990. Since its founding in 1986, the Ellis Island Medal of Honor has been officially recognized by the U.S. Congress as one of the United States' most prestigious awards. Past recipients include six presidents of the United States, as well as esteemed Americans such as Frank Sinatra, Lee Iacocca, Quincy Jones, Muhammad Ali, Nobel laureate Elie Wiesel, Louis Zamperini and Rosa Parks. Among other 2017 recipients are Dr. Buzz Aldrin, Mindy Grossman, Governor John Kasich, Indra Nooyi and global honoree Malala Yousafzai. A full listing of the 2017 Ellis Island Medal of Honor recipients is available here. Prior to joining ALSAC as CEO in 2009, Shadyac, Jr., served as the chairman and president of the ALSAC Board of Directors. He was an active board member since 2000. A practicing attorney for 27 years, he also worked as a partner in the Washington D.C./Northern Virginia law firm, Feldesman Tucker Leifer Fidell, LLP. He has been named the CEO of the Year from Inside Memphis Business and the Corporate Social Responsibility's CEO of the Year. St. Jude Children's Research Hospital is leading the way the world understands, treats and defeats childhood cancer and life-threatening diseases. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments invented at St. Jude have helped push the overall childhood cancer survival rate from 20 percent to more than 80 percent since the hospital opened more than 50 years ago. St. Jude is working to drive the overall survival rate for childhood cancer to 90 percent, and we won't stop until no child dies from cancer. St. Jude freely shares the discoveries it makes, and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children. Families never receive a bill from St. Jude for treatment, travel housing or food – because all a family should worry about is helping their child live. Join the St. Jude mission by visiting, liking St. Jude on Facebook ( and following us on Twitter (@stjude). To view the original version on PR Newswire, visit:

The Request for Proposals (RFP) issued by NCCN and Pfizer strongly encourages proposals that address the use of clinical pathways in community centers, low-resource centers, and centers that focus on the treatment of underserved patients with cancer. All U.S.-based organizations, including NCCN Member Institutions, community affiliates of NCCN Member Institutions and other academic medical centers, and community cancer centers are encouraged to submit proposals. "NCCN recognizes the emerging role of evidence-based clinical care pathways in cancer, and we are pleased to once again align with Pfizer IGLC to improve the quality of care of people with breast cancer, particularly those in underserved communities across the United States," said Susan Most, RN, MBA Director, Clinical Operations, NCCN ORP. The RFP seeks proposals in two specific areas of interest: The NCCN ORP, organized to obtain funding to support scientifically meritorious research studies at NCCN Member Institutions and other centers, leads the organization for review and evaluation of applications. A review committee, led by NCCN and including a medical representative from Pfizer, will decide which proposals will receive funding. Grant funding will be provided by Pfizer IGLC. The RFP deadline is June 26, 2017. For more information about NCCN ORP and view the RFP, visit About the National Comprehensive Cancer Network The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The NCCN Member Institutions are: Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Wisconsin Carbone Cancer Center, Madison, WI; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT. To view the original version on PR Newswire, visit:

The full list of Reader's Digest Trusted Brands can be found in the publication's June issue, which goes on sale today, May 16, and online at Carnival continues to introduce exciting onboard features and programming to build upon its brand promise of providing fun, memorable vacations at a great value, while keeping up with changing consumer trends and preferences. Last year marked the launch of the new Carnival Vista, a groundbreaking 133,500-ton ship that introduced such one-of-a-kind features as SkyRide, a bike-ride-in-the-sky attraction, as well as the first IMAX Theatre at sea, the first brewery on a North American-based cruise ship and Family Harbor, with special family-friendly accommodations and a private lounge. To commemorate Carnival Vista's U.S. arrival, the company hosted an overnight event aboard the ship in New York for military families in support of Operation Homefront, the national nonprofit that builds strong, stable and secure military families.  The event included a concert by country music superstar Carrie Underwood and the ship's official naming with Deshauna Barber – the first woman serving in the U.S. military to be named Miss USA – presiding over the ceremonies as godmother. Throughout its fleet, Carnival continues to build upon its commitment to providing exceptional, friendly and attentive service through initiatives such as the Carnival Service Values, a comprehensive program that has redefined the company's culture of service and reinforces the importance of  offering a fun, welcoming environment, both on board and ashore. Additionally, Carnival and its employees support a wide range of charitable and social service agencies and organizations in its homeports throughout the U.S.  The company also serves as the Official Celebration Partner of St. Jude Children's Research Hospital, its primary charitable partner. Since launching Care to Play: Carnival for St. Jude Kids program in 2010, Carnival has donated more than $13 million in the fight against childhood cancer. "We work very hard to maintain our distinction as 'America's Cruise Line' and being named 'Most Trusted Cruise Line in America' three years running is a wonderful validation of our efforts at providing fun, quality and memorable vacations our guests," said  Christine Duffy, president of Carnival Cruise Line. To learn more about Carnival Cruise Line, visit For reservations, contact any travel agent or call 1-800-CARNIVAL. Carnival can also be found on: Facebook, Instagram, Twitter and YouTube. Journalists also can visit Carnival's media site, or follow the line's PR department on Twitter at Carnival Cruise Line, part of Carnival Corporation & plc (NYSE/LSE: CCL; NYSE: CUK), is "The World's Most Popular Cruise Line®" with 25 ships operating three- to 16-day voyages to The Bahamas, Caribbean, Mexican Riviera, Alaska, Hawaii, Canada, New England, Bermuda, Europe, Cuba, Australia, New Zealand and the Pacific Islands. Two 133,500-ton Vista class ships are currently scheduled for delivery - Carnival Horizon in 2018 and an as-yet-unnamed vessel in 2019. Additionally, two new 180,000-ton ships are scheduled to enter service in 2020 and 2022. These are findings from an Ipsos Connect study conducted for Reader's Digest from November 15 to November 23, 2016. For the survey, a sample of 5,500 U.S. adults were interviewed online.  The precision of online polls is measured using a credibility interval. In this case, the poll has a credibility interval of plus or minus 1.6 percentage points.  The data was weighted to U.S. Census data by age, gender, income and geography. Statistical margins of error are not applicable to online surveys. All sample surveys may be subject to other sources of error, including, but not limited to coverage error and measurement error. Where figures do not sum to 100, this is due to the effects of rounding. Winning brands were determined by absolute vote and confirmed to be statistically significant from the other brand(s). In any category where the winning brand was not significantly different from the other brands, a follow up question was asked to determine the brand winner. The highest brand is designated a category winner only if it is statistically significant at the 95 percent confidence level, when compared to the next highest brand. If a tie still existed, the secondary tie breaker was determined by direct performance of trust compared to other most trusted brand. Reader's Digest, a Trusted Media Brands, Inc. brand, simplifies and enriches consumers' lives by discovering and expertly selecting the most interesting ideas, stories, experiences and products in health, home, family, food, finance and humor. Reader's Digest is available online at; in print; via digital download on iPad, mobile apps and tablets; and can be accessed via its social media channels: Facebook, Twitter, Instagram, YouTube, Pinterest and Google+. Trusted Media Brands, Inc. comprises a network of engaged, active readers who genuinely connect with its blend of uplifting and enduring expertly-curated family, food, health, home improvement, finance and humor content digitally, via magazines and books, social media, and events and experiences. Founded in 1922 by DeWitt Wallace as Reader's Digest Association, one of the first user-generated content publishers, Trusted Media Brands, Inc. is headquartered in New York City. For more information, visit To view the original version on PR Newswire, visit:

Loading Research Hospital collaborators
Loading Research Hospital collaborators